Nautilus Biotechnolgy
NAUT
83 hedge funds and large institutions have $155M invested in Nautilus Biotechnolgy in 2022 Q2 according to their latest regulatory filings, with 22 funds opening new positions, 18 increasing their positions, 18 reducing their positions, and 21 closing their positions.
1,750% more call options, than puts
Call options by funds: $37K | Put options by funds: $2K
1% more funds holding
Funds holding: 82 → 83 (+1)
1.18% more ownership
Funds ownership: 45.03% → 46.2% (+1.2%)
5% more first-time investments, than exits
New positions opened: 22 | Existing positions closed: 21
0% more funds holding in top 10
Funds holding in top 10: 4 → 4 (0)
0% more repeat investments, than reductions
Existing positions increased: 18 | Existing positions reduced: 18
36% less capital invested
Capital invested by funds: $244M → $155M (-$88.8M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$7.63M |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
+$1.58M |
| 3 |
State Street
Boston,
Massachusetts
|
+$1.47M |
| 4 |
Northern Trust
Chicago,
Illinois
|
+$1.15M |
| 5 |
CAM
Crown Advisors Management
Larkspur,
California
|
+$931K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$3.65M |
| 2 |
Franklin Resources
San Mateo,
California
|
-$1.99M |
| 3 |
PVI
Pura Vida Investments
New York
|
-$1.06M |
| 4 |
Millennium Management
New York
|
-$858K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
-$639K |
NAUT Hedge Fund Activity: Q2 2022 in Review
83 of the 5,959 institutional investors tracked by Wall St. Rank reported a position in Nautilus Biotechnolgy (NAUT) for Q2 2022, worth a combined $155M — down 36% from $244M a quarter earlier.
Buyers outnumbered sellers: 22 funds opened new NAUT positions and 21 closed out — a net gain of 1 holder — while 18 added to existing stakes and 18 trimmed.
The largest buyer was BlackRock, adding an estimated $7.63M. The largest seller was Sphera Funds Management, exiting entirely with an estimated $3.65M sold.
- 83 institutional investors held Nautilus Biotechnolgy (NAUT) as of Q2 2022, up from 82 in Q1 2022.
- Funds reported $155M of Nautilus Biotechnolgy stock for Q2 2022, down 36% quarter-over-quarter.
- 22 funds opened new Nautilus Biotechnolgy positions in Q2 2022 and 21 closed out, a net change of +1 holder.
- The largest Nautilus Biotechnolgy buyer in Q2 2022 was BlackRock, an estimated $7.63M added.
- The largest Nautilus Biotechnolgy seller in Q2 2022 was Sphera Funds Management, an estimated $3.65M sold.
Based on aggregated 13F filings for Q2 2022.